Close Menu

Meridian Bioscience

Meridian's Diagnostics segment grew 2 percent lifted by a 10 percent increase in revenues from the illumigene molecular product line.

The tests are the eighth and ninth assays to be cleared for use on the firm's Illumigene platform and provide results in less than one hour.

The assays use specimens from symptomatic patients for the qualitative detection and differentiation of HSV-1 and HSV-2 with results generated within one hour. 

The revenue increase was driven by growth in Meridian's Diagnostics segment and particularly sales of its Illumigene product line.

Fluidigm and Meridian Bioscience led the gainers in the GenomeWeb Index for the month, while T2 Bio and PacBio's shares saw the biggest drops. 

Meridian received the CE mark for two new Illumigene molecular diagnostic tests for Chlamydia trachomatis and Neisseria gonorrhoeae.

HiberGene hopes to launch its assays, based on loop-mediated isothermal amplification, in the EU in the third quarter of this year.

Diagnostics revenues at the company jumped 5 percent organically driven in part by a 16 percent increase in sales of illumigene molecular diagnostic products.

The firm said the office will help it strengthen ties with and provide better service to it Chinese customers.

The investment bank downgraded Meridian Bioscience from a prior Market Perform rating, noting challenges to its molecular diagnostics business. 

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.